Accelerate Diagnostics Q1 2024 GAAP EPS $(0.88) Misses $(0.72) Estimate, Sales $2.921M Miss $3.000M Estimate
Accelerate Diagnostics Q1 2024 GAAP EPS $(0.88) Misses $(0.72) Estimate, Sales $2.921M Miss $3.000M Estimate
加速诊断2024年第一季度GAAP每股收益（0.88）未达到预期（0.72）美元，销售额292.1万美元未达到3000万美元的预期
Accelerate Diagnostics (NASDAQ:AXDX) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.72) by 22.22 percent. This is a 48.54 percent increase over losses of $(1.71) per share from the same period last year. The company reported quarterly sales of $2.921 million which missed the analyst consensus estimate of $3.000 million by 2.63 percent. This is a 3.88 percent increase over sales of $2.812 million the same period last year.
Accelerate Diagnostics（纳斯达克股票代码：AXDX）公布的季度亏损为每股0.88美元，比分析师普遍预期的0.72美元（0.72美元）低22.22％。这比去年同期每股亏损1.71美元（1.71美元）增长了48.54％。该公司公布的季度销售额为292.1万美元，比分析师普遍预期的3000万美元低2.63％。这比去年同期的281.2万美元销售额增长了3.88％。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。